Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GMAB with free AI briefings, catalyst countdowns, and dilution alerts.

GMAB · Genmab A/S

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.9B Cash on Hand
CF+ Cash Runway
1.6% Short Interest
$65.01 Analyst Target (11)
Follow GMAB by email Get an email when GMAB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GMAB, unsubscribe in one click. Privacy

📣 What GMAB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Epcoritamab
FDA approved May 2023 · Epkinly
Diffuse Large B-Cell Lymphoma Phase 3 · NCT05578976 Active not recruiting
Tisotumab Vedotin Cervical Cancer Phase 4 · NCT06952660 Recruiting
Pegylated Liposomal Doxorubicin Hydrochloride Platinum-resistant Ovarian Cancer Phase 3 · NCT06619236 Active not recruiting
Investigator's choice Head and Neck Squamous Cell Carcinoma Phase 3 · NCT06496178 Active not recruiting
Investigator's Choice Chemotherapy Diffuse Large B-cell Lymphoma Phase 3 · NCT04628494 Active not recruiting
Irinotecan Colorectal Cancer Phase 3 · NCT07775287 Recruiting
mFOLFOX6 Left-sided Colorectal Cancer Phase 3 · NCT07702032 Recruiting
Fluorouracil Colorectal Cancer Phase 3 · NCT07775287 Recruiting
Petosemtamab (MCLA-158) Head and Neck Squamous Cell Carcinoma Phase 3 · NCT06525220 Active not recruiting
PLD Platinum-Sensitive Ovarian Cancer Phase 3 · NCT07564141 Recruiting
Rinatabart Sesutecan Platinum-resistant Ovarian Cancer Phase 3 · NCT06619236 Active not recruiting
Vincristine Diffuse Large B-Cell Lymphoma Phase 3 · NCT05578976 Active not recruiting
Acasunlimab PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or… Phase 3 · NCT06635824 Active not recruiting
Doxorubicin Diffuse Large B-Cell Lymphoma Phase 3 · NCT05578976 Active not recruiting
FOLFIRI Left-sided Colorectal Cancer Phase 3 · NCT07702032 Recruiting
Bendamustine Diffuse Large B-Cell Lymphoma Phase 1/2 · NCT04663347 Active not recruiting

Also used in these trials (approved or third-party drugs, not GMAB's own candidates): Gemcitabine Hydrochloride, Leucovorin, Oxaliplatin, Paclitaxel, Pembrolizumab, Prednisone, Rituximab, Topotecan, Carboplatin, Cetuximab, Bevacizumab, Cyclophosphamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GMAB holds $1.9B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GMAB files for a raise →

Get the full GMAB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GMAB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.